Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its financials for Q3 2023 ended September 30, 2023, showing:

See full Q2 results.

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.